ArticleCureus2026
Effect of Single Perineural Injection of Platelet Rich Plasma on Nerve Function in Hansen's Disease With Truncal Neuropathy: An Interventional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background A large number of people with leprosy suffer from neuropathy and its associated complications. Platelet-rich plasma (PRP) is a simple therapy by which concentrations of natural growth factors are obtained that accelerate axonal recovery. With the intent to find an effective option for the improvement of neuropathy in Hansen's disease, perineural injection of autologous PRP was used in this study. This study aims to investigate the potential therapeutic efficacy of perineural injection of PRP in alleviating the effects of neuropathy associated with Hansen's disease. Methodology A cohort of 30 patients with Hansen's disease experiencing ulnar or common peroneal neuropathy were administered a single perineural injection of autologous PRP (1 ml). Evaluations were conducted by a group of three investigators at baseline, six, and twelve weeks, encompassing two-point sensory discrimination, total sensory impairment area, nerve conduction study (NCS) parameters, Screening Activity Limitation and Safety Awareness Scale (SALSA) score, hand function, and extrinsic foot muscle power. Adverse effects were meticulously recorded. Results Significant improvements were observed in two-point discrimination, sensory loss area, hand dynamometry scores, and foot muscle power (p<0.05). The SALSA score exhibited a significant enhancement at the 12-week mark. Motor NCS demonstrated a substantial increase in amplitude, while sensory NCS revealed a noteworthy decrease in latency and an increase in conduction velocity at the 12-week assessment. No adverse effects were documented, aside from transient pain at the injection site for one or two days. As the follow-up period in this study was 12 weeks, the long-term effects of peri-neural injection of PRP on Hansen's neuropathy could not be assessed. COVID-19 also had an impact on the follow-up visits of the participants, resulting in three patients being lost to follow-up. Conclusion This study suggests that perineural injection of autologous PRP could be a safe and promising therapeutic option for Hansen's neuropathy. However, further research and long-term follow-up studies are imperative to establish its sustained efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.